Lucid Diagnostics Inc. (NASDAQ:LUCD) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET

Company Participants

Adrian Miller – Vice President-Investor Relations

Lishan Aklog – Chairman and Chief Executive Officer

Dennis McGrath – Chief Financial Officer

Conference Call Participants

Ross Osborn – Cantor Fitzgerald

Ed Woo – Ascendiant Capital

Kyle Mikson – Canaccord

Operator

Greetings, welcome to the Lucid Diagnostics Business Update Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] And please note that this conference is being recorded.

I will now turn the conference over to Adrian Miller, Vice President of Investor Relations. Thank you, sir. You may begin.

Adrian Miller

Thanks operator. Good afternoon, everyone. This is Adrian Miller, Vice President-Investor Relations at Lucid Diagnostics. Thank you for participating in today's business update call. Joining me today on the call are Dr. Lishan Aklog, Chairman and CEO of Lucid Diagnostics; along with Dennis McGrath, Chief Financial Officer of Lucid Diagnostics.

The press release announcing our business update and financial results is available on Lucid's website. Please take a moment to read the disclaimer about forward-looking statements in the press release, the business update press release and this conference call, both include forward-looking statements, and these forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from the statements made. Factors that could cause actual results to differ are described in the disclaimer and in our filings with the Securities and Exchange Commission.

For a list and description of these and other important risks and uncertainties that may affect future operations, see Part I and Item 1A entitled Risk Factors in Lucid's most recent annual report on Form 10-K filed with the SEC and the subsequent update filed on quarterly reports as Form 10-Q and any subsequent Form 8-K filings. Except as required by law, Lucid disclaims any intentions or obligations to publicly update or revise any forward-looking statements to reflect changes in expectations or in events, conditions or circumstances on which those expectations may be based or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

So with that, I would like to turn the call over to Lishan Aklog. Dr. Aklog.

Lishan Aklog

Thank you, Adrian, and good afternoon, everyone. I'm happy to report that Lucid Diagnostics is making excellent progress on all fronts and that we're laying a solid foundation for driving our long-term growth strategy. We continue to drive EsoGuard commercialization, expand our sales infrastructure, execute the second stage of our Lucid Test Center rollout, transition to our own fully staffed laboratory and update our clinical trial strategy to best serve our growth strategy.